Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors

Bauer, Todd MTodd MBauerSantoro, ArmandoArmandoSantoroCHIA-CHI LINGarrido-Laguna, IgnacioIgnacioGarrido-LagunaJoerger, MarkusMarkusJoergerGreil, RichardRichardGreilSpreafico, AnnaAnnaSpreaficoYau, ThomasThomasYauGoebeler, Maria-ElisabethMaria-ElisabethGoebelerHütter-Krönke, Marie LuiseMarie LuiseHütter-KrönkePerotti, AntonellaAntonellaPerottiJuif, Pierre-EricPierre-EricJuifLu, DarleneDarleneLuBarys, LouiseLouiseBarysCremasco, VivianaVivianaCremascoPelletier, MarcMarcPelletierEvans, HelenHelenEvansFabre, ClaireClaireFabreDoi, ToshikikoToshikikoDoi2024-01-122024-01-122023-11-292051-1426https://scholars.lib.ntu.edu.tw/handle/123456789/638447NIS793 is a human IgG2 monoclonal antibody that binds to transforming growth factor beta (TGF-β). This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors.enDrug Therapy, Combination; Immunotherapy; Non-Small Cell Lung Cancer; Programmed Cell Death 1 Receptor; Therapies, Investigational[SDGs]SDG3Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumorsjournal article10.1136/jitc-2023-007353380303032-s2.0-85178651810https://api.elsevier.com/content/abstract/scopus_id/85178651810